Non-Hodgkin Lymphoma

Phase II study of Proleukin plus rituximab initiated in lymphoma patients

Published in Cancer Weekly, July 6th, 2004

Chiron Corporation (CHIR) announced that it has initiated a new phase II study of Proleukin (aldesleukin) interleukin-2 (IL-2) plus rituximab in rituximab-naive patients with low-grade non-Hodgkin lymphoma (NHL) to determine the combination's potential in patients receiving rituximab for the first time.

This large, randomized, controlled multi-national study will employ translational medicine to determine the Fc gamma RIIIa genotypes of patients and identify those who are more likely to respond to treatment.

Chiron initiated the new phase II study based on preliminary data from its ongoing phase II study of Proleukin (subcutaneous 14 MIU thrice...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry